Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Inflammatory Bowel Diseases

Free Subscription 15.06.2026 3 Aliment Pharmacol Ther 4 Am J Gastroenterol 1 BMC Gastroenterol 3 Clin Gastroenterol Hepatol 2 Clin Res Hepatol Gastroenterol 1 Dis Colon Rectum 3 Gastroenterol Hepatol 1 Gastroenterology 5 Inflamm Bowel Dis 6 J Crohns Colitis 4 Lancet Gastroenterol Hepatol 1 Minerva Gastroenterol (Torino) 1 N Engl J Med

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Aliment Pharmacol Ther

1. VISSER EH, Voshaar MAO, van Linschoten RCA, Bodelier AGL, et al
   Editorial: Inflammatory Bowel Disease Care Pathways-Improving Quality, but Not at Increased Cost. Authors' Reply.
   Aliment Pharmacol Ther. 2026 Jun 10. doi: 10.1111/apt.70780.
   PubMed        
   
   
2. BARREIRO-DE ACOSTA M, Zabana Y, Nieto-Garcia L, Poncela M, et al
   Real-World Effectiveness of Risankizumab in Refractory Crohn's Disease: The RISANCROHN Study From the ENEIDA Registry.
   Aliment Pharmacol Ther. 2026 Jun 10. doi: 10.1111/apt.70783.
   PubMed         Abstract available
   
   
3. KOPPELMAN LJM, Loveikyte R, Goetgebuer RL, van der Marel S, et al
   Clinical Trial: Predicting Response to Iron Therapy in Patients With Active Inflammatory Bowel Disease Using Hepcidin and Functional Iron Indices: A Multicentre Randomised Trial.
   Aliment Pharmacol Ther. 2026 Jun 8. doi: 10.1111/apt.70775.
   PubMed         Abstract available
   
   

   
   Am J Gastroenterol

4. CALDERA F, Farraye FA
   Guidelines in Practice: Preventive Care in Inflammatory Bowel Disease.
   Am J Gastroenterol. 2026 Jun 8. doi: 10.14309/ajg.0000000000004070.
   PubMed        
   
   
5. CHODEN T, Mathew AJ, Goffinet A, Scott A, et al
   Impact of Upadacitinib on Cardiovascular Events and Lipid Values in Older Inflammatory Bowel Disease Patients with Baseline Cardiovascular Risk.
   Am J Gastroenterol. 2026 Jun 9. doi: 10.14309/ajg.0000000000004074.
   PubMed         Abstract available
   
   
6. SLEIMAN J, Pillai GV, Chirra P, Gandhi NS, et al
   Development of a Computed Tomography Enterography Based Radiomics Model to Characterize Inflammation, Fibrosis and Smooth Muscle Thickening in Stricturing Crohn's Disease.
   Am J Gastroenterol. 2026 Jun 9. doi: 10.14309/ajg.0000000000004073.
   PubMed         Abstract available
   
   
7. TSE CS, Lewis JD, Horst SN, Saha S, et al
   Inflammatory Bowel Diseases-Specific Cognitive Behavioral Therapy Delivered Through Telehealth Reduces Disability: Addressing Disability Effectively With Psychosocial Telemedicine Pragmatic Randomized Controlled Trial.
   Am J Gastroenterol. 2026;121:1435-1444.
   PubMed         Abstract available
   
   

   
   BMC Gastroenterol

8. GU Y, Zhang X, Gu L, Zou D, et al
   Effectiveness and safety of vedolizumab in real-world studies in Asian patients with inflammatory bowel disease: a systematic review and meta-analysis.
   BMC Gastroenterol. 2026 Jun 12. doi: 10.1186/s12876-026-04975.
   PubMed         Abstract available
   
   

   
   Clin Gastroenterol Hepatol

9. DANESE S, Goetsch M, Peyrin-Biroulet L, Yarur AJ, et al
   The Efficacy and Safety of Etrasimod in Mildly to Moderately Active Ulcerative Colitis: Results from the Phase 2 GLADIATOR Trial.
   Clin Gastroenterol Hepatol. 2026 Jun 4:S1542-3565(26)00405.
   PubMed         Abstract available
   
   
10. MEYER A, Weill A, Carbonnel F, Dray-Spira R, et al
    Risk of lymphoma associated with biologics and immunosuppressants in inflammatory bowel disease patients: a nationwide nested case-control study.
    Clin Gastroenterol Hepatol. 2026 Jun 10:S1542-3565(26)00413.
    PubMed         Abstract available
    
    
11. WONG ECL, Jairath V, Dulai PS, Marshall JK, et al
    Comparing Onset of Efficacy of Biologic and Small Molecule Therapies in Biologic-Naive Ulcerative Colitis: A Post-Hoc Analysis.
    Clin Gastroenterol Hepatol. 2026 Jun 4:S1542-3565(26)00400.
    PubMed         Abstract available
    
    

    
    Clin Res Hepatol Gastroenterol

12. SAFAR H DR, Sheka D DR, Rivas A DR, Cino M DR, et al
    USING CLINICAL FACTORS TO PREDICT TREATMENT OUTCOMES AND HEALTH-CARE UTILIZATION IN CROHN'S DISEASE PATIENTS INITIATING ADVANCED THERAPIES.
    Clin Res Hepatol Gastroenterol. 2026 Jun 11:102869.
    PubMed         Abstract available
    
    
13. AMIOT A, Ahres A, Stefanescu C, Meyer A, et al
    Association of bowel urgency, disease activity and disability in patients with inflammatory Bowel Disease: A cross-sectional study from the GETAID.
    Clin Res Hepatol Gastroenterol. 2026 Jun 5:102861.
    PubMed         Abstract available
    
    

    
    Dis Colon Rectum

14. MIRANDE MD, Ore AS, Flaherty EG, Reynolds IS, et al
    Risk Factors for Small Bowel Crohn's Disease Recurrence after Total Proctocolectomy.
    Dis Colon Rectum. 2026 Jun 12. doi: 10.1097/DCR.0000000000004329.
    PubMed         Abstract available
    
    

    
    Gastroenterol Hepatol

15. GUTIERREZ-RIOS L, Calafat M, Vayreda E, Manosa M, et al
    Faecal calprotectin to monitor response to treatment escalation for endoscopic postoperative recurrence of Crohn's disease.
    Gastroenterol Hepatol. 2026;49:502654.
    PubMed         Abstract available
    
    
16. FISSAH M, Bennouar S, Rechach A, Haddab L, et al
    Unveiling hidden malnutrition in IBD: A cross-sectional multi-tool analysis reveals high prevalence beyond weight-based assessment.
    Gastroenterol Hepatol. 2026;49:502662.
    PubMed         Abstract available
    
    
17. ORDAS I, Caballol B, Giordano A, Esteve M, et al
    Position statement of the spanish working group on crohn's disease and ulcerative colitis (geteccu) on the diagnosis and management of acute severe ulcerative colitis.
    Gastroenterol Hepatol. 2026 Jun 4:502815. doi: 10.1016/j.gastrohep.2026.502815.
    PubMed         Abstract available
    
    

    
    Gastroenterology

18. SUN L, Ye W
    Beyond Calorie Counting: Is Circadian Alignment Key to Metabolic Health in Crohn's Disease?
    Gastroenterology. 2026 Jun 10:S0016-5085(26)06971.
    PubMed        
    
    

    
    Inflamm Bowel Dis

19. TAO M, Zhang Z, Dai L, Zeng Y, et al
    Metagenomic insights into potential horizontal transfer of resistance/virulence genes in gut microbiota from patients with Crohn disease.
    Inflamm Bowel Dis. 2026 Jun 7:izag090. doi: 10.1093.
    PubMed         Abstract available
    
    
20. HUANG JS, Bauman LE, Katibian D, Polk DB, et al
    Between-visit care represents a substantial and underrecognized component of health care utilization in pediatric inflammatory bowel disease.
    Inflamm Bowel Dis. 2026 Jun 11:izag097. doi: 10.1093.
    PubMed         Abstract available
    
    
21. ABDUL REHMAN K, Us Sehar N, Akram U, Fatima E, et al
    Clinical significance of isolated periappendiceal red patch in ulcerative colitis: A systematic review, meta-analysis, and meta-regression.
    Inflamm Bowel Dis. 2026 Jun 9:izag092. doi: 10.1093.
    PubMed         Abstract available
    
    
22. TAMILARASAN AG, Chiu C, Bestawros D, Oborn S, et al
    Transmural healing is significantly associated with prevention of clinical relapse in Crohn's disease.
    Inflamm Bowel Dis. 2026 Jun 9:izag041. doi: 10.1093.
    PubMed         Abstract available
    
    
23. SIGVARDSSON I, Ludvigsson J, Lerchova T, Imberg H, et al
    Timing of complementary food introduction is not associated with inflammatory bowel disease risk: A prospective birth cohort study.
    Inflamm Bowel Dis. 2026 Jun 9:izag093. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Crohns Colitis

24. D'AMICO F, Fanizzi F, Dal Buono A, Gabbiadini R, et al
    Effectiveness and safety of mirikizumab in patients with moderate-to-severe ulcerative colitis: the miri real multicenter study.
    J Crohns Colitis. 2026;20:jjag062.
    PubMed         Abstract available
    
    
25. GIMENO-PITARCH L, Iborra M, Crespo A, Sanchis L, et al
    Risk of symptomatic leishmaniasis in patients with inflammatory bowel disease receiving biologic therapy in an endemic Mediterranean region: a population-based case-control study.
    J Crohns Colitis. 2026;20:jjag067.
    PubMed         Abstract available
    
    
26. TRIVIC MAZURANIC I, Aloi M, Bramuzzo M, Chiantese C, et al
    Histological activity predicts relapse in pediatric ulcerative colitis despite mucosal healing: a multicenter study from the pediatric IBD Porto group of ESPGHAN.
    J Crohns Colitis. 2026;20:jjag074.
    PubMed         Abstract available
    
    
27. TSOUNIS E, Forlano R, Voulgaris T, Bosgana P, et al
    Deep learning layer-specific collagen quantification correlates with activity and is associated with outcomes in Crohn's disease.
    J Crohns Colitis. 2026;20:jjag075.
    PubMed         Abstract available
    
    
28. PARONI M, Faggiano C, Righetti C, Dusetti I, et al
    Pro-inflammatory intestinal Th17-cells are tissue-resident, accumulate in the epithelia in Crohn's disease, and predict unresponsiveness to vedolizumab.
    J Crohns Colitis. 2026;20:jjag055.
    PubMed         Abstract available
    
    
29. MENYS A, Naim I, Barber J, Patel K, et al
    The CONTEXT trial: Real world clinical use of GIQuant-a motility MRI based activity biomarker for small bowel Crohn's disease.
    J Crohns Colitis. 2026;20:jjag037.
    PubMed         Abstract available
    
    

    
    Lancet Gastroenterol Hepatol

30. OLDENBURG L, Haanappel AEG, D'Haens GR, Bemelman WA, et al
    Upfront medical or surgical treatment in Crohn's disease - Authors' reply.
    Lancet Gastroenterol Hepatol. 2026;11:552-553.
    PubMed        
    
    
31. NOOR NM, Fleshner PR, Melmed GY, Siegel CA, et al
    Upfront medical or surgical treatment in Crohn's disease.
    Lancet Gastroenterol Hepatol. 2026;11:551-552.
    PubMed        
    
    
32. BANCIL AS, Giles EM, Fitzpatrick J
    Cyclic exclusive enteral nutrition in paediatric Crohn's disease.
    Lancet Gastroenterol Hepatol. 2026;11:550.
    PubMed        
    
    
33. PIGNEUR B, Ruemmele FM
    Cyclic exclusive enteral nutrition in paediatric Crohn's disease - Authors' reply.
    Lancet Gastroenterol Hepatol. 2026;11:550-551.
    PubMed        
    
    

    
    Minerva Gastroenterol (Torino)

34. MARTELLA P, Schiavoni E, Napolitano D, Cocchieri A, et al
    The influence of self-care-related constructs on medication adherence in inflammatory bowel disease: a scoping review.
    Minerva Gastroenterol (Torino). 2026 Jun 11. doi: 10.23736/S2724-5985.26.04126.
    PubMed         Abstract available
    
    

    
    N Engl J Med

35. GHARAHDAGHI N, Yeh PJ, Ceron-Gutierrez L, Griffin H, et al
    Interleukin-10 Autoantibodies and HLA-DRB1*01:03 in Inflammatory Bowel Disease.
    N Engl J Med. 2026;394:2212-2222.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum